Pathos AI entered into a strategic collaboration with Bristol Myers Squibb and Tempus AI to develop artificial intelligence tools for drug development in Alzheimer's disease and other neurological conditions.

Overview Debates Related claims Topics Sources

In the Beth Israel trial, consenting patients will interact with MAI-DxO alongside standard medical care to compare its recommendations against decisions made by human doctors.

MAI-DxO achieves lower estimated costs by judiciously ordering fewer unnecessary medical tests and procedures during sequential patient evaluations.

Estimated diagnostic work-up costs for MAI-DxO were up to 20% to 50% lower than those designed by human physicians in case simulations.

Microsoft plans to conduct real-world clinical testing of MAI-DxO with Beth Israel Deaconess Medical Center in Boston to evaluate patient triage in emergency department waiting rooms.

The strategic agreements mark Pathos AI's expansion from oncology into neurological conditions, beginning with Alzheimer's disease treatments.

Pathos AI will apply its Foundry platform to Tempus AI's neurological dataset to track patient outcomes and speed research into Alzheimer's disease biology.

Pathos AI agreed to license up to 500,000 de-identified patient records for Alzheimer's or neurological conditions from Tempus AI under a five-year agreement worth up to $55 million, at 100,000 records per year.

Bristol Myers Squibb gained non-exclusive strategic access to Pathos AI's Foundry platform across its broader portfolio, plus three-year exclusive rights to use the platform for its neuroscience development programs.

MAI-DxO running on OpenAI's GPT-5 reduced the estimated per-case running cost by about $3,000 on complex cases while raising accuracy from 78.9% to over 83%.

Bristol Myers Squibb agreed to make fixed payments totaling $137.5 million through 2031 under a Statement of Work with Tempus AI for oncology data and analytic services.

A side letter agreement between Tempus AI, Pathos AI, and Bristol Myers Squibb restricts Tempus AI from licensing its neurology records to other parties for a specified period.

Early Alzheimer's symptoms such as hearing impairment can reduce engagement in physical activity, triggering accelerated cognitive and memory decline.

A UK study of 1,139 people over age 50 found that moderate to vigorous physical activity reduced dementia risk by 34% to 50% over eight to ten years.

Study co-author Dr. You Zhou stated that combining gut bacteria and digestive chemicals distinguished individuals with mild cognitive impairment from healthy people with high accuracy.

Brain health benefits against Alzheimer's tau protein accumulation appeared at 3,000 steps daily, with an optimal protective plateau between 5,000 and 7,500 steps daily.

A study tracking almost 300 older adults found that physical activity did not reduce toxic amyloid plaques, but reduced signs of dementia by almost half in more active participants.

In older adults with early brain signs of Alzheimer's, physical activity reduced the accumulation of misfolded tau proteins in specific brain areas over nine to 11 years, according to a study tracking participants with pedometers.

A 2022 UK study tracking 78,430 people for seven years using wrist accelerometers found a 25% reduction in dementia risk at 3,800 daily steps, rising to 50% at 9,800 steps.

Cardiovascular and stroke risk factors including elevated cholesterol, poor sleep, high blood pressure, and diabetes increase dementia risk alongside physical inactivity.

On October 20, 2026, AstraZeneca announced a collaboration with Oracle to leverage artificial intelligence, cloud, and healthcare data capabilities to refine clinical research